Dragon Pharmaceuticals has sold its EPO business to an unidentified purchaser for $2.1 million. Pointing out that the product contributed just 3% of its revenues, Dragon said it preferred to concentrate on its higher growth antibiotics business. A market study, according to Dragon, shows the EPO market may be trending lower over the next three years. Dragon also announced that antibiotic sales have increased from $31.2 million for all of 2005 to about $60 million for just the first nine months of 2007, which was a 60% increase over the comparable 2006 figure. More details...

Stock Symbol: (OTCBB: DRUG)